{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:46:14Z","timestamp":1781541974146,"version":"3.54.5"},"reference-count":50,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T00:00:00Z","timestamp":1496102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:p>This study investigated the disposition of coagulation factor VIII activity in 754 patients with moderate to severe hemophilia A following the administration of moroctocog alfa, a B\u2010domain deleted recombinant factor VIII. Data analyzed included patients aged 1 day to 73 years enrolled in 13 studies conducted over a period of 20 years in 25 countries. A two\u2010compartment population pharmacokinetic model with a baseline model described the pooled data well. Body size, age, inhibitors, race, and analytical assay were identified as significant predictors of factor VIII disposition. In addition, simulations of prophylactic dosing schedules in several pediatric cohorts showed large variability and suggest that younger patients would require higher weight\u2010adjusted doses than adolescents to achieve target factor VIII trough activity when receiving every other day or twice weekly dosing.<\/jats:p>","DOI":"10.1002\/cpt.716","type":"journal-article","created":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T23:22:56Z","timestamp":1493076176000},"page":"977-988","source":"Crossref","is-referenced-by-count":21,"title":["Elucidation of Factor VIII Activity Pharmacokinetics: A Pooled Population Analysis in Patients With Hemophilia A Treated With Moroctocog Alfa"],"prefix":"10.1111","volume":"102","author":[{"given":"JA","family":"Abrantes","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Biosciences Uppsala University Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EI","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biosciences Uppsala University Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Korth\u2010Bradley","sequence":"additional","affiliation":[{"name":"Pfizer Inc Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Harnisch","sequence":"additional","affiliation":[{"name":"Global Clinical Pharmacology Pfizer Sandwich UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"J\u00f6nsson","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biosciences Uppsala University Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,30]]},"reference":[{"key":"e_1_2_9_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01123-X"},{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02909.x"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11420-009-9140-9"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13215"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.3406_1.x"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02239.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0699-3"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0676-x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-360594"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01334.x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3180311384"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12816"},{"key":"e_1_2_9_13_1","unstructured":"European Medicines Agency (EMA).Assessment report for Refacto AF. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Assessment_Report_\u2010_Variation\/human\/000232\/WC500049011.pdf> (2009). Accessed 22 February 2017."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620712464509"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01924.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1972.tb03468.x"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199222050-00005"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.136275"},{"key":"e_1_2_9_19_1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1055\/s-0038-1649589","article-title":"Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study.","volume":"70","author":"Conlan M.G.","year":"1993","journal-title":"Thromb. Haemost."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02237.x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-007-0090-0"},{"key":"e_1_2_9_22_1","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1182\/blood.V80.8.1998.1998","article-title":"Maturation of the hemostatic system during childhood.","volume":"80","author":"Andrew M.","year":"1992","journal-title":"Blood"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02604.x"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03703.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01810.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1214711"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13294"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-09-0760"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90108-8"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90109-X"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01420.x"},{"key":"e_1_2_9_32_1","article-title":"Results of a single\u2010dose, randomized, double\u2010blind, 2\u2010period crossover pharmacokinetic study of B\u2010domain deleted recombinant FVIII (BDDrFVIII), current manufacturing process (ReFacto\u00ae), and BDDrFVIII, albumin\u2010free manufacturing process (ReFacto AF)","volume":"102","author":"Recht M.","year":"2003","journal-title":"Blood"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02027.x"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.168"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01068.x"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.4"},{"key":"e_1_2_9_37_1","unstructured":"Beal S.L. BoeckmannA.J. BauerR.J.NONMEM 7.3.0 Users Guides(ICON Development Solutions Hanover MD 1989\u20132013)."},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.24"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-008-9094-4"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01113502"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02353466"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199630050-00001"},{"key":"e_1_2_9_43_1","unstructured":"DHSS\/MRC Group on Obesity Research.James W.P.T. Great Britain. Department of Health and Social Security & Medical Research Council (Great Britain).Research on Obesity: A Report of the DHSS\/MRC Group(Her Majesty's Stationary Office London England UK 1976)."},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.2307\/1165809"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/33.1.27"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011970125687"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9255-z"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100241"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-016-9487-8"},{"key":"e_1_2_9_50_1","unstructured":"Hyattsville MD: U.S. Department of Health and Human Services Centers for Disease Control and Prevention. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data (1999\u20132010) <http:\/\/www.cdc.gov\/nchs\/nhanes\/sas_viewer.htm>. Accessed 21 November2016."}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.716","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:32:24Z","timestamp":1699363944000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,30]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1002\/cpt.716"],"URL":"https:\/\/doi.org\/10.1002\/cpt.716","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,30]]}}}